A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Latest Information Update: 22 May 2024
At a glance
- Drugs PLX-2853 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Opna Bio; Plexxikon
- 14 Dec 2021 Final Results of a Phase 1b Study of BET Inhibitor PLX2853presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 10 Aug 2021 Status changed from active, no longer recruiting to completed.
- 24 Jun 2021 Status changed from recruiting to active, no longer recruiting.